Market Access News | pharmaphorum

News

FDA rejects ImmunityBio’s bladder cancer drug

Shares in ImmunityBio were in freefall today after it revealed the FDA had rejected its marketing application for Anktiva as a treatment for bladder cancer.

News

FDA clears Rexulti as first drug for Alzheimer’s agitation

Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodege

News

NICE okays glucose sensors in kids with type 2 diabetes

Children with type 2 diabetes in the UK who have to undergo the stressful chore of monitoring blood glucose with multiple finger prick blood tests every day could soon see

News

FDA advisors backs first OTC contraceptive

An FDA advisory committee has unanimously voted in favour of approval for what could become the first oral contraceptive to be made available in the US without a doctor’s

News

FDA kicks off review of Roche’s Vabysmo in RVO

Roche could be just months away from a third indication for its eye drug Vabysmo that could accelerate its already fast growth in the US.

News

England widens pharmacist role to relieve GP pressure

Pharmacies in England will be able to prescribe medicines for seven common conditions without a GP prescription under new proposals intended to relieve the pressure on pri

FDA rejects ImmunityBio’s bladder cancer drug

FDA clears Rexulti as first drug for Alzheimer’s agitation

NICE okays glucose sensors in kids with type 2 diabetes

FDA advisors backs first OTC contraceptive

FDA kicks off review of Roche’s Vabysmo in RVO

England widens pharmacist role to relieve GP pressure

NHS study will pick apart mental illness with data science

How to meet your physicians where they are online

News

Editor's Picks